Regor Therapeutics scores $90m Series B
Regor Therapeutics, a clinical-stage biotechnology company focused on treating cancer, immune disorders and metabolic diseases, has closed $90 million in Series B financing.
Regor Therapeutics, a clinical-stage biotechnology company focused on treating cancer, immune disorders and metabolic diseases, has closed $90 million in Series B financing.
Copyright PEI Media
Not for publication, email or dissemination